CG Oncology (CGON) Income from Continuing Operations (2023 - 2026)
CG Oncology (CGON) posted Income from Continuing Operations of 442993000.0 for Q1 2026, down 968.46% on a QoQ basis from 41461000.0 in Q4 2025, and down 263.8% year-over-year from 270446119.33 in Q1 2025.
CG Oncology (CGON) Income from Continuing Operations (2023 - 2026) Analysis & Trends
CG Oncology's Income from Continuing Operations history runs 4 years deep, the most recent figure standing at 442993000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 263.8% year-over-year to 442993000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 867063000.0 (down 72.32% YoY) and the FY2025 annual result came in at 359388000.0, down 83.18% from the prior year.
- Income from Continuing Operations was 442993000.0 for Q1 2026 at CG Oncology, down from 41461000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 8946000.0 in Q1 2023 and bottomed at 442993000.0 in Q1 2026.
- A 4-year average of 128250846.15 and a median of 121768000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations slumped 2673.52% — and 2025, when it jumped 50.92%.
- CG Oncology's Income from Continuing Operations stood at 16551000.0 in 2023, then sank by 92.52% to 31864000.0 in 2024, then plunged by 30.12% to 41461000.0 in 2025, then plunged by 968.46% to 442993000.0 in 2026.
- Business Quant data shows CGON's Income from Continuing Operations at 442993000.0 in Q1 2026, 41461000.0 in Q4 2025, and 234434000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | CG Oncology | 5.86 Bn | 5.86 Bn | -1.88 Mn | -442.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -442.99 Mn |
| Dec 31, 2025 | -41.46 Mn |
| Sep 30, 2025 | -234.43 Mn |
| Jun 30, 2025 | -148.18 Mn |
| Mar 31, 2025 | -121.77 Mn |
| Dec 31, 2024 | -31.86 Mn |
| Sep 30, 2024 | -177.59 Mn |
| Jun 30, 2024 | -171.94 Mn |
| Mar 31, 2024 | -248.12 Mn |
| Dec 31, 2023 | -16.55 Mn |
| Sep 30, 2023 | -11.82 Mn |
| Jun 30, 2023 | -11.60 Mn |
| Mar 31, 2023 | -8.95 Mn |